WallStSmart

Motorola Solutions Inc (MSI)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 442% more annual revenue ($63.32B vs $11.68B). MSI leads profitability with a 18.4% profit margin vs 11.8%. MSI appears more attractively valued with a PEG of 2.37. MSI earns a higher WallStSmart Score of 62/100 (C+).

MSI

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 9.0Value: 4.3Quality: 3.5
Piotroski: 3/9Altman Z: 1.41

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 6.0Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MSI.

PFEUndervalued (+31.4%)

Margin of Safety

+31.4%

Fair Value

$37.44

Current Price

$25.68

$11.76 discount

UndervaluedFair: $37.44Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MSI3 strengths · Avg: 9.0/10
Return on EquityProfitability
104.2%10/10

Every $100 of equity generates 104 in profit

Market CapQuality
$72.00B9/10

Large-cap with strong market position

Operating MarginProfitability
27.8%8/10

Strong operational efficiency at 27.8%

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

MSI4 concerns · Avg: 3.3/10
PEG RatioValuation
2.374/10

Expensive relative to growth rate

P/E RatioValuation
34.0x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
26.4x2/10

Trading at 26.4x book value

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : MSI

The strongest argument for MSI centers on Return on Equity, Market Cap, Operating Margin. Profitability is solid with margins at 18.4% and operating margin at 27.8%. Revenue growth of 12.3% demonstrates continued momentum.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : MSI

The primary concerns for MSI are PEG Ratio, P/E Ratio, Piotroski F-Score. Debt-to-equity of 4.05 is elevated, increasing financial risk.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

MSI profiles as a mature stock while PFE is a value play — different risk/reward profiles.

MSI carries more volatility with a beta of 0.94 — expect wider price swings.

MSI is growing revenue faster at 12.3% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Bottom Line

MSI scores higher overall (62/100 vs 55/100), backed by strong 18.4% margins and 12.3% revenue growth. PFE offers better value entry with a 31.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Motorola Solutions Inc

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Motorola Solutions, Inc., is an American data communications and telecommunications equipment provider that succeeded Motorola, Inc., following the spinoff of the mobile phone division into Motorola Mobility in 2011. The company is headquartered in Chicago, Illinois.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?